The role of chemokines in *Schistosoma mansoni* infection: insights from human disease and murine models

Adriano LS Souza, Silvio R Sousa-Pereira*, Mauro M Teixeira, José R Lambertucci*, Antonio L Teixeira*/+

Laboratório de Imunofarmacologia, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas *Divisão de Infectologia e Medicina Tropical, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena 190, 30130-100 Belo Horizonte, MG, Brasil

Chemokines are a superfamily of low-molecular-weight cytokines that were initially described for their chemoattractant activity. It is now clear chemokines have several other activities that modulate immune processes. More than 50 chemokines ligands and at least 19 receptors have been described to date. Depending on the number of N-terminal cysteine residues, chemokines are grouped in the subfamilies CXC, CC, C or CX3C. A growing body of evidence suggests a role for chemokines in the pathogenesis of several inflammatory diseases. Our studies involving mice and humans infected with *Schistosoma mansoni* suggest an important role of the chemokine CCL3 and its receptors (CCR1 and CCR5) in the pathogenesis of severe schistosomiasis. We suggest that the differential activation of CCR1 or CCR5 during the course of schistosomiasis may dictate the outcome of the disease.

Key words: schistosomiasis - chemokines - inflammation

While many good reviews have been published on the pathogenesis of schistosomiasis and the role of cytokines on tissue and vascular events leading to the main alterations associated with disease morbidity and mortality (Vennervald & Dunne 2004), the specific contribution of chemokines to these changes has not been addressed in details. Accumulating data in the recent literature justifies the need for an integrated re-examination of this issue with a focus on this important group of inflammatory mediators. Thus, this review aims at confronting complementary evidence from human and mice studies to sum up that chemokines are indeed relevant co-players in the intricate mechanisms that explain why some schistosomiasis patients deal relatively well with the infection while others are prone to develop severe forms of the disease.

Chemokines: structure and function

Chemokines belong to the superfamily of low-molecular-weight cytokines that were initially described for their chemotactic activity. They are important mediators of cell migration. However, it is clear that chemokines affect several other processes, including differentiation and activation, tissue specific homing of leukocytes under physiological conditions, infiltration of cells in sites of tissue injury. By performing the activities described above, chemokines have been shown to play a relevant role in angiogenesis, infectious, and autoimmune diseases (Mackay 2001). More than 50 chemokine ligands and at least 19 signalizing chemokine receptors are known today in both humans and mice (Charo & Ransohoff 2006).

Despite the low sequence similarity between some chemokines, an important feature of this class of molecules is their disulfide-stabilized tertiary structure composed of three beta sheets linked by short loops with a carboxy-terminal alpha helix in a Greek key formation. Depending on the number of N-terminal cysteine residues they are grouped in the subfamilies CXC (two N-terminal cysteines separated by one amino-acid residue), CC (two directly linked cysteines), C (only one N-terminal cysteine) or CX3C (two N-terminal cysteines separated by three aminoacid residues) (Olson & Ley 2002). This classification is helpful since there seems to be some specificity regarding the cellular types responding to a certain group of chemokines. Nonetheless, chemokines commonly bind to several receptors, and cells, in turn, may bear multiple types of chemokine receptors, which may result in considerable superposition or redundancy of responses.

Differently from other cytokines that act on tyrosine kinase receptors, all chemokines signal via G protein-coupled seven transmembrane spanning receptors (Proudfoot et al. 2003). The nomenclature of chemokine receptors is directly based on the type of chemokine that binds them. Six years have passed since the IUPHAR deliberation on the systematic nomenclature of chemokine ligands and receptors (Murphy et al. 2000). Although the system was initially developed for human chemokines, it may be extended to rodents as well. Thus, this nomenclature will be employed in this review.

Chemokines in schistosomiasis

Abundant literature attests the role of chemokines in the physiopathology of several diseases including atopic dermatitis, leishmaniosis, rheumatoid arthritis, multiple sclerosis, asthma, pulmonary sarcoidosis, sepsis, atherosclerosis, HIV infection, ulcerative colitis among others.
Some studies have focused on the role of chemokines in schistosomiasis. Data obtained from murine models suggest that chemokines dictate the type and intensity of inflammatory infiltrate during the granulomatous response against egg antigens (Qiu et al. 2001). For instance, the chemokine macrophage inflammatory protein-1a (MIP-1a/CCL3) was released after embolization of schistosome eggs into the lungs of immunized mice. Interestingly the antibody neutralization of CCL3 decreased the size of the granuloma (Lukacs et al. 1994a, b). In addition, CCR1-deficient mice exhibited a 40% reduction in egg-induced pulmonary granulomas corroborates this assumption (Gao et al. 1997). It is important to note that data from CCR1-deficient mice must not be considered equivalent to the results involving CCL3 knockouts as CCL3 may bind to other receptors, including CCR5 (Post et al. 1995, Nibbs et al. 1997). The studies described only evaluated the inflammatory response after injection of eggs into animals. In our experiments in *Schistosoma mansoni*-infected mice, we found that CCL3-deficient mice displayed decreased liver eosinophilic peroxidase activity (EPO) and hydroxyproline content (Souza et al. 2005). These findings paralleled reduced wound burden and egg content in this organ. The mechanisms responsible for the reduced parasitic burden are still unclear. However, we found a significant reduction in granuloma area compared to wild type animals and this effect was clearly dependent on the role of the chemokine on pathology (Souza et al. 2005). These results indicate that the granulomatous response and schistosomiasis is less severe in the absence of CCL3.

Similar results were also shown for other knockout mice. When CCR2-deficient mice were subjected to the model of venous injection and subsequent lung embolization with schistosome egg antigen (SEA)-coupled beads, a decrease in granuloma size, attributed to the reduction of the number of lymphocytes, was observed (Warmington et al. 1999). The mRNA levels for interleukin(IL)-4 and interferon(IFN)-γ were found to be decreased, while there were increased mRNA levels for CCR2 ligands such as CCL2, CCL7, and CCL12. This result may suggest that the synthesis of CCR2 ligands would be regulated by a receptor activation-induced negative feedback mechanism (Warmington et al. 1999). The effect of CCR2 depletion on the course of *S. mansoni* infection has not been reported to date.

Intravenous injection of schistosoma eggs into CCR8-deficient mice resulted in impaired Th-2 cytokine synthesis and significantly reduced eosinophilic infiltration in lung granulomas (Chensue et al. 2001). The reduction in Th-2 cytokine synthesis in CCR8-deficient mice corroborates the fact that this chemokine receptor mediates selective expression of Th-2 lymphocytes. It is worth mentioning that, with the exception of our study, the data discussed previously were based on a model of intravenous injection of either eggs or antigen-coupled beads, which causes pulmonary embolization followed by granuloma formation. Although this model has the advantage of synchronizing the kinetics of granuloma development, it does not take into account the host-parasite cross-talk that may have profound influence on the regulation of inflammatory response. Moreover the lung is not the most affected organ by naturally occurring granulomatous response in schistosomiasis.

The CCL3 chemokine seemed to be particularly relevant in schistosomiasis. This assumption was reinforced by studies involving human subjects. We found that, when compared with uninfected individuals, infected patients had elevated plasma concentrations of CCL3, CCL5, and CCL11 (Falcão et al. 2002). When patients were grouped according to disease severity (intestinal x hepatosplenic), subjects with increased plasma concentration of CCL3 (> 400 pM) had a 10 times greater risk of displaying hepatosplenic form of the disease (Falcão et al. 2002). This preliminary data was confirmed in a second subset of chronically infected patients who had been classified by ultrasonography (Souza et al. 2005). It was also demonstrated that peripheral blood mononuclear cells (PBMC) from infected patients, when exposed in vitro to SEA-coupled beads, produced high levels of CCL3 and that this production was antigen-specific (Falcão et al. 2002). Treatment of PBMC from hepatosplenic patients with met-RANTES, a CCR1, and CCR5 antagonist, was capable of inhibiting the cellular reactivity in this in vitro granuloma model. However the treatment of PBMC from intestinal patients determined an exacerbation of the cellular response. These apparently conflicting results remained an issue of difficult interpretation and prompt us to suggest that the balance between the expression of these two chemokine receptors, CCR1 and CCR5, are crucial to the outcome of schistosomiasis infection (see below). It has also been shown that exacerbation of the in vitro granulomatous response induced by nitro L-arginine methyl ester (L-NAME), a nitric oxidase inhibitor, treatment is associated with increases in CCL3 in the culture supernatant of human PBMC (Oliveira et al. 1999).

Recently, we also investigated the chemokine levels in serum and CSF of schistosomal myeloradiculopathy (SMR) patients (Sousa-Pereira et al. 2006). SMR is the most common neurological form of *S. mansoni* infection and seems to be determined by the inflammatory response to schistosomal eggs ectopically deposited in the nervous system (Nobre et al. 2001, Silva et al. 2004). SMR patients presented increased serum levels of CCL11 and CCL24 when compared to controls. In contrast to the determinations in serum, there were no differences in the concentration of chemokines in CSF of SMR patients when compared to neurologically healthy controls. This unexpected finding may be consistent with a lack of intrathecal production of the chemokines (Sousa-Pereira et al. 2006).

The CCL3 receptors, CCR1 and CCR5, are expressed in a series of cell types, including neutrophils, monocytes, macrophages, T and B lymphocytes, eosinophils, dendritic cells (DC), natural killer (NK) cells, thymocytes, plate-
cytes, named TCD4+ IL-17, were crucial for the development of these exacerbated lesions (Rutitizky et al. 2005), and importantly, that these lymphocytes were characterized by the synthesis of the cytokines tumor necrosis factor (TNF)-α and IL-6 and chemokines CCL2, CCL3, and CXCL8 (Prof. Miguel Stadecker, pers. commun.). It is worth emphasizing that the same chemokines were shown to be elevated in the plasma of patients suffering the hepatosplenic form of schistosomiasis (Falcão et al. 2002).

**A model for the balance of expression of two chemokine receptors and the outcome of *S. mansoni* infection**

The main question in schistosomiasis research relates to the explanation of why the great percentage of *S. mansoni* infected hosts display only mild symptoms, while a minority suffers from severe, sometimes life threatening, hepatosplenic symptoms (Fallon 2000). Conflicting data from different species infected with *S. mansoni* should also be reconciled in a comprehensive model of disease pathogenesis. Based on what has been discussed above, we propose a model in which the balance between two chemokine receptors, namely CCR1 and CCR5, may exert a crucial role on the final presentation of *S. mansoni* infection. We do not suggest, however, that the roles of other mediators are to be disregarded, but that the two chemokine receptors are important players in this multi-faceted inflammatory context.

It is known that other chemokines exhibit significant affinity for the receptors used by CCL3. For instance, CCL5, CCL14, CCL15, and CCL23 are CCR1 agonists while CCL4, CCL5, and CCL8 are CCR5 agonists (Murphy et al. 1997). Thus, a given chemokine can act on different chemokine receptors, while one specific receptor may be the target of several chemokines what would suggest that this system operates with considerable redundancy. However, this view is not accepted by all researchers, since some suggest that some level of compartmentalization exists in the chemokine system. This scenario is depicted, for instance, in some reviews that deal with the rational design of new drugs based on the action of chemokines (Proudfoot et al. 2000, 2003, Proudfoot 2002, Johnson et al. 2004).

We suggest that the influence of the balance between the CCR1 and CCR5 chemokine receptors on the clinical presentation of schistosomiasis depends on the occurrence of a fine temporal and spatial tuning of the action of chemokines to reach specificity of response. The Figure is a graphic representation of this hypothesis. We propose that the majority of infected hosts or patients, who present mild form of disease, are able to develop an adaptive immune response in which there is preponderance of CCR5 receptor activation over CCR1. On the other hand, severe forms of disease would result from unbalanced chemokine receptor activation towards an increased activation of CCR1 over CCR5. CCR1 activation would be predominantly mediated by CCL3, while CCR5 activation by CCL5. The reason for the need of fine mechanisms regulating spatial-temporal specificity of CCL3 and CCL5 resides in complementary experimental observations from various research groups indicating that these chemokines exhibit apparently opposing activities regarding the clinical presentation of disease, despite sharing nearly identical receptor affinity.

Evidence that supports the idea that CCL3 has a harmful role in schistosomiasis derives from the following experimental observations: (1) a correlation between high...
levels of CCL3 and the presentation of hepatosplenic disease in schistosomiasis patients (Falcão et al. 2002, Souza et al. 2005, Sousa-Pereira et al. 2006); (2) the development of milder disease in a model of CCL3-deficient S. mansoni infected mice (Souza et al. 2005); (3) a 40% inhibition in lung granulomas in CCR1 knockout mice subjected to intravenous injection of S. mansoni eggs (Gao et al. 1997); and (4) the phenotypic description of a class of IL-17-producing T helper lymphocyte (Rutitzky et al. 2005), that is also characterized by producing the chemokines CCL2, CCL3, and CXCL8, with a demonstrated role in the development of severe lesions associated with increased morbidity and mortality in schistosomiasis (Prof. Stadecker, pers. commun.).

Other set of evidences suggests that another chemokine, most likely CCL5, plays a modulatory role in the immunopathology of schistosomiasis preventing the emergence of severe forms of the disease: (1) a more severe schistosomiasis infection in CCR5-deficient mice (Souza 2005); (2) a correlation between the risk of presentation of periportal fibrosis and elevated TNF-α associated with low CCL5 concentrations in the supernatant of PBMC from schistosomiasis patients stimulated with SEA (Booth et al. 2004); (3) an increase in 50% on the size of pulmonary granulomas from mice subjected to intravenous injection of SEA-coupled beads and treated with antibody against CCL5 (Chensue et al. 1999); (4) the observation of increased CCR5 expression on lymphocytes from intestinal patients and low expression of the same receptor in both control and hepatosplenic individuals (Prof. Andréa Teixeira, pers. commun.); and (5) the tendency towards exacerbation of cellular reactivity of PBMC from intestinal patients treated with met-RANTES in the in vitro granuloma model, contrary to the intense inhibition observed with cells from hepatosplenic patients (Falcão et al. 2002). In hepatosplenic patients, the modulatory CCR5 wing would be absent. Thus, in these patients, the CCR1 and CCR5 combined antagonism of met-RANTES equals the isolate inhibition of CCR1 activation, causing granuloma reduction. In intestinal patients, whose CCR5 expression supersedes that of CCR1, met-RANTES activity turns to be harmful.

In summary, accumulating evidence in the literature suggests that chemokines are more than epiphenomena of adaptive immune responses. This important group of mediators may be related to the outcome of infectious diseases at least in the context of S. mansoni infection. Moreover the presence of key chemokines in plasma or serum, besides reflecting pathogenic mechanisms, may be used as surrogated markers of disease severity. This support the efforts which are being made to design new drugs that could act on the chemokine system and we are hopeful that these drugs may be used for the management of several inflammatory conditions.

REFERENCES


